Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

C4 Therapeutics (CCCC) EBITDA: 2019-2025

Historic EBITDA for C4 Therapeutics (CCCC) over the last 6 years, with Sep 2025 value amounting to -$32.0 million.

  • C4 Therapeutics' EBITDA fell 34.82% to -$32.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$119.4 million, marking a year-over-year decrease of 14.70%. This contributed to the annual value of -$105.1 million for FY2024, which is 18.17% up from last year.
  • Latest data reveals that C4 Therapeutics reported EBITDA of -$32.0 million as of Q3 2025, which was down 22.83% from -$26.1 million recorded in Q2 2025.
  • In the past 5 years, C4 Therapeutics' EBITDA registered a high of -$16.3 million during Q4 2021, and its lowest value of -$35.9 million during Q4 2022.
  • Its 3-year average for EBITDA is -$28.9 million, with a median of -$28.6 million in 2024.
  • As far as peak fluctuations go, C4 Therapeutics' EBITDA tumbled by 120.62% in 2022, and later skyrocketed by 49.54% in 2024.
  • Quarterly analysis of 5 years shows C4 Therapeutics' EBITDA stood at -$16.3 million in 2021, then slumped by 120.62% to -$35.9 million in 2022, then climbed by 5.39% to -$34.0 million in 2023, then fell by 2.94% to -$35.0 million in 2024, then slumped by 34.82% to -$32.0 million in 2025.
  • Its last three reported values are -$32.0 million in Q3 2025, -$26.1 million for Q2 2025, and -$26.3 million during Q1 2025.